Association of INVIRASE® (saquinavir mesylate) with significant dose-dependent prolongations of QT and PR intervals in healthy volunteers

Invirase (saquinavir mesylate)

Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform healthcare professionals of important new safety information regarding the use of INVIRASE^® (saquinavir mesylate) and significant dose-dependent prolongations of QT and PR intervals in healthy volunteers.
INVIRASE is authorized for the treatment of HIV-1 infected adult patients. INVIRASE should only be given in combination with ritonavir and other antiretroviral medicinal products.
 

Saquinavir ATC Code: J05AE01

Warning

Hoffmann-La Roche Limited would like to bring attention to the fact that dose-dependent prolongations of QT and PR intervals have been observed in healthy volunteers taking ritonavir-boosted Invirase.

Evidence

Fair

Reference

http://hc-sc.gc.ca/dhp-mps/medeff/advisories-av...